Ken Herrmann
University of Duisburg-Essen
CancerInternal medicineRadiologyPET-CTPathologyMagnetic resonance imagingOncologyProspective cohort studyMedical physicsPositron emission tomographyChemotherapyLymphomaProstate cancerNuclear medicineRadionuclide therapyIn patientCancer researchRadiation therapyClinical trialHistopathologyMedicine
523Publications
67H-index
10.3kCitations
Publications 532
Newest
#1Britta Heinze (University of Würzburg)H-Index: 6
#2Andreas Schirbel (University of Würzburg)H-Index: 27
Last. Martin Fassnacht (University of Würzburg)H-Index: 79
view all 0 authors...
Adrenal tumors represent a diagnostic and therapeutic challenge. Promising results have been obtained through targeting the cytochrome P450 enzymes CYP11B1 and CYP11B2 for molecular imaging, and [123/131I]iodometomidate ([123/131I]IMTO) has even been successfully introduced as a theranostic agent. As this radiopharmaceutical shows rapid metabolic inactivation, we aimed at developing new improved tracers. Several IMTO derivatives were newly designed by replacing the unstable methyl ester by diffe...
Source
#1Nathalie Heynickx (UGent: Ghent University)
#2Ken Herrmann (UCLA: University of California, Los Angeles)H-Index: 67
Last. An AertsH-Index: 13
view all 5 authors...
Abstract At present, prostate cancer remains the second most occurring cancer in men, in Europe. Treatment efficacy for therapy of advanced metastatic disease, and metastatic castration-resistant prostate cancer in particular is limited. Prostate-specific membrane antigen (PSMA) is a promising therapeutic target in prostate cancer, seeing the high amount of overexpression on prostate cancer cells. Clinical investigation of PSMA-targeted radionuclide therapy has shown good clinical efficacy. Howe...
Source
#1Francesco Giammarile (IAEA: International Atomic Energy Agency)H-Index: 23
#2Roberto C. Delgado Bolton (UR: University of La Rioja)H-Index: 8
Last. Enrique Estrada L (IAEA: International Atomic Energy Agency)
view all 0 authors...
As a follow-up to the international survey conducted by the International Atomic Energy Agency (IAEA) in April 2020, this survey aims to provide a situational snapshot of the COVID-19 impact on nuclear medicine services worldwide, 1 year later. The survey was designed to determine the impact of the pandemic at two specific time points: June and October 2020, and compare them to the previously collected data. A web-based questionnaire, in the same format as the April 2020 survey was disseminated ...
Source
Background: This study investigated the performance of simultaneous 18F-FDG PET/MRI of the breast as a platform for comprehensive radiomics analysis for breast cancer subtype analysis, hormone receptor status, proliferation rate and lymphonodular and distant metastatic spread. Methods: One hundred and twenty-four patients underwent simultaneous 18F-FDG PET/MRI. Breast tumors were segmented and radiomic features were extracted utilizing CERR software following the IBSI guidelines. LASSO regressio...
Source
#1Robert SeifertH-Index: 10
Last. Thomas DeckerH-Index: 72
view all 0 authors...
INTRODUCTION Addition of cyclin-dependent 4/6 kinase (CDK4/6) inhibitors to endocrine therapy is standard of care in the treatment of women with advanced hormone receptor-positive HER2-negative breast cancer. However, the predictive factors for the treatment response to CDK4/6 inhibitor therapy are poorly elucidated. Early changes in the by [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) uptake of tumors receiving different kinds of therapy have proven to reliably predict treatme...
Source
#3Benedikt M. Schaarschmidt (University of Duisburg-Essen)H-Index: 9
Background: To evaluate the potential of simultaneously acquired 18F-FDG PET- and MR-derived quantitative imaging data sets of primary soft-tissue sarcomas for the prediction of neoadjuvant treatment response, the metastatic status and tumor grade. Methods: A total of 52 patients with a high-risk soft-tissue sarcoma underwent a 18F-FDG PET/MR examination within one week before the start of neoadjuvant treatment. For each patient, the maximum tumor size, metabolic activity (SUVs), and diffusion-r...
Source
#1Andrei Gafita (UCLA: University of California, Los Angeles)H-Index: 4
#2Hui Wang (TUM: Technische Universität München)H-Index: 2
Last. Matthias Eiber (TUM: Technische Universität München)H-Index: 55
view all 22 authors...
Background: We aimed to systematically determine the impact of tumor burden on the 68Ga-prostate-specific membrane antigen-11 (68Ga-PSMA) PET biodistribution by the use of quantitative measurements. Methods: This international multicenter retrospective analysis included 406 men with prostate cancer who received 68Ga-PSMA PET/CT. Of these, 356 had positive findings and were stratified by quintiles into very low (Q1, ≤25 ml), low (Q2, 25-189 ml), moderate (Q3, 189-532 ml), high (Q4, 532-1355 ml) a...
Source
#1Ken HerrmannH-Index: 67
#2Clemens Kratochwil (DKFZ: German Cancer Research Center)H-Index: 54
Last. Roland HustinxH-Index: 53
view all 5 authors...
Source
#1Maja Guberina (University of Duisburg-Essen)H-Index: 4
#2C. Poettgen (University of Duisburg-Essen)H-Index: 5
Last. Martin Stuschke (University of Duisburg-Essen)H-Index: 55
view all 18 authors...
Purpose/Objective(s): The aim of this follow-up analysis of the ESPATUE phase-3 trial was to explore the prognostic value of post-induction chemotherapy PET metrics in patients with stage III non-small cell lung cancer (NSCLC) who were assigned to receive definitive chemoradiotherapy. Materials/Methods: All eligible patients stage IIIA (cN2) and stage IIIB of the trial received induction chemotherapy consisting of 3 cycles of cisplatin/paclitaxel and chemoradiotherapy up to 45 Gy/1.5 Gy per frac...
Source
Source